Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Valion Bio announced Thomas Jensen as its new Board Chair and highlighted that its drug Entolimod has secured $35.6 million in government funding, along with Fast Track and Orphan Drug designations from the FDA.
Valion Bio, Inc. appointed director Dean Zikria as interim CEO and named Thomas Jensen Board Chair and Jared Malbin Audit Chair; Sheryle Bolton left the Board.Material DetailsContext by AI AnalystThis is an early-to-mid stage governance move as the company prioritizes Entolimod and partnership purs…